-
Je něco špatně v tomto záznamu ?
Is shorter also better in the treatment of Clostridioides difficile infection
M. Duricek, K. Halmova, M. Krutova, B. Sykorova, J. Benes
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, pozorovací studie
NLK
Free Medical Journals
od 1996 do Před 1 rokem
Open Access Digital Library
od 1996-01-01
PubMed
38661207
DOI
10.1093/jac/dkae119
Knihovny.cz E-zdroje
- MeSH
- antibakteriální látky * terapeutické užití aplikace a dávkování MeSH
- Clostridioides difficile * genetika účinky léků klasifikace MeSH
- fidaxomicin * terapeutické užití aplikace a dávkování MeSH
- klostridiové infekce * farmakoterapie mikrobiologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- ribotypizace * MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- vankomycin * terapeutické užití aplikace a dávkování MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
OBJECTIVES: To assess the effectiveness of shortened regimens of vancomycin or fidaxomicin in the treatment of Clostridioides difficile infection (CDI). METHODS: Adult patients with CDI hospitalized from January 2022 to May 2023 were included in this observational study. In patients with CDI treated with vancomycin or fidaxomicin, antibiotic treatment was discontinued after either 5 or 7 days of vancomycin or 5 days of fidaxomicin if there was a clinical response and improvement in laboratory parameters. The control cohort was treated with the standard 10 day regimen of either vancomycin or fidaxomicin. The follow-up was 60 days. Causative C. difficile strains were characterized by ribotyping and toxin gene detection when available. RESULTS: Twenty-five patients (median age 76 years) received shortened treatment with vancomycin (n = 21), or fidaxomicin (n = 4). Five cases fulfilled the criteria for severe CDI. Twenty-three patients completed follow-up; two died from causes other than CDI, and two developed recurrent CDI (8.0%). Ribotypes (RTs) 001 and 014 were the most prevalent with 20% each. In two C. difficile isolates, binary toxin genes were detected (RTs 078 and 023). In the control group of 22 patients recurrent CDI developed in 5 patients (22.7%). No statistically significant differences were found between the groups. CONCLUSIONS: Shortened treatment regimens for CDI with vancomycin and fidaxomicin were shown to be effective in our cohort of patients compared with 10 days of treatment. The recurrence rate was lower in the study group. A larger, prospective, double-blind, randomized, multicentre study is needed to support our findings.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013585
- 003
- CZ-PrNML
- 005
- 20240905133435.0
- 007
- ta
- 008
- 240725s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/jac/dkae119 $2 doi
- 035 __
- $a (PubMed)38661207
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Duricek, M $u Department of Infectious Diseases, 3rd Faculty of Medicine, Charles University and University Hospital Bulovka, Budínova 67/2, 180 81, Praha 8, Prague, Czech Republic $1 https://orcid.org/0009000664490434
- 245 10
- $a Is shorter also better in the treatment of Clostridioides difficile infection / $c M. Duricek, K. Halmova, M. Krutova, B. Sykorova, J. Benes
- 520 9_
- $a OBJECTIVES: To assess the effectiveness of shortened regimens of vancomycin or fidaxomicin in the treatment of Clostridioides difficile infection (CDI). METHODS: Adult patients with CDI hospitalized from January 2022 to May 2023 were included in this observational study. In patients with CDI treated with vancomycin or fidaxomicin, antibiotic treatment was discontinued after either 5 or 7 days of vancomycin or 5 days of fidaxomicin if there was a clinical response and improvement in laboratory parameters. The control cohort was treated with the standard 10 day regimen of either vancomycin or fidaxomicin. The follow-up was 60 days. Causative C. difficile strains were characterized by ribotyping and toxin gene detection when available. RESULTS: Twenty-five patients (median age 76 years) received shortened treatment with vancomycin (n = 21), or fidaxomicin (n = 4). Five cases fulfilled the criteria for severe CDI. Twenty-three patients completed follow-up; two died from causes other than CDI, and two developed recurrent CDI (8.0%). Ribotypes (RTs) 001 and 014 were the most prevalent with 20% each. In two C. difficile isolates, binary toxin genes were detected (RTs 078 and 023). In the control group of 22 patients recurrent CDI developed in 5 patients (22.7%). No statistically significant differences were found between the groups. CONCLUSIONS: Shortened treatment regimens for CDI with vancomycin and fidaxomicin were shown to be effective in our cohort of patients compared with 10 days of treatment. The recurrence rate was lower in the study group. A larger, prospective, double-blind, randomized, multicentre study is needed to support our findings.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a klostridiové infekce $x farmakoterapie $x mikrobiologie $7 D003015
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a Clostridioides difficile $x genetika $x účinky léků $x klasifikace $7 D016360
- 650 12
- $a antibakteriální látky $x terapeutické užití $x aplikace a dávkování $7 D000900
- 650 12
- $a vankomycin $x terapeutické užití $x aplikace a dávkování $7 D014640
- 650 12
- $a fidaxomicin $x terapeutické užití $x aplikace a dávkování $7 D000077732
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a ribotypizace $7 D021521
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Halmova, K $u Department of Infectious Diseases, 3rd Faculty of Medicine, Charles University and University Hospital Bulovka, Budínova 67/2, 180 81, Praha 8, Prague, Czech Republic
- 700 1_
- $a Krutova, M $u Department of Medical Microbiology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000245119430
- 700 1_
- $a Sykorova, B $u Department of Clinical Microbiology, University Hospital Bulovka, Prague, Czech Republic
- 700 1_
- $a Benes, J $u Department of Infectious Diseases, 3rd Faculty of Medicine, Charles University and University Hospital Bulovka, Budínova 67/2, 180 81, Praha 8, Prague, Czech Republic
- 773 0_
- $w MED00002514 $t Journal of antimicrobial chemotherapy $x 1460-2091 $g Roč. 79, č. 6 (2024), s. 1413-1417
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38661207 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905133429 $b ABA008
- 999 __
- $a ok $b bmc $g 2143408 $s 1225451
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 79 $c 6 $d 1413-1417 $e 20240603 $i 1460-2091 $m Journal of antimicrobial chemotherapy $n J Antimicrob Chemother $x MED00002514
- LZP __
- $a Pubmed-20240725
